Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting
Links shared publicly online about this topic.
- 381total visits
Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting
Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.
View full resource at news-medical.net
Tags: Multiple Sclerosis, Drug, Phase 2 Clinical Trial, Sanofi-Aventis, Genzyme
Most Recently Shared on April 8, 2011 at 5:46 am By:
Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting: Genzyme, a subsidiary of sanofi-a... http://bit.ly/esQJ2s
Advertisement
